Prenylation of aromatic secondary metabolites is an important process involved in the biosynthesis of many biologically active compounds in plants and animals. Many prenylated natural products have been shown to exhibit very good anti-tumor, anti inflammatory and antimicrobial activities. The addition of prenyl side chain to an aromatic secondary metabolite often affects its pharmacological activity. The aim of this review is to examine the influence of the prenyl side chain on the pharmacological activities of some classes of aromatic secondary metabolites and the potential application of prenylation in the development of novel drugs

No abstract

The ethanol extracts of Syzygium aromaticum flower bud were tested for anti-nociceptive and antiinflammatory effects in mice and Wistar rats which were carried out using acetic acid-induced abdominal contractions in mice and formalin-induced hind paw edema in Wistar rats. Three doses of the ethanol extract (50, 100, and 200mg/kg body weight i.p.) were used for both studies. The extract had an LD 50 of 565.7 mg/kg body weight intraperitoneally in mice. The extracts produced significant effect (P<0.05) at all the three doses. Similarly, the anti-nociceptive activity produced significant effects (P<0.05) at all the three doses of the extract. The result supports the local use of the plant in painful and inflammatory conditions.

This is first report on the isolation of antifungal substances through bioassay-guided assay from A. paniculata. Our finding justifies the use of A. paniculata in folk medicines for the treatment of fungal skin infections.

In recent years, there is emerging evidence that isoflavonoids, either dietary or obtained from traditional medicinal plants, could play an important role as a supplementary drug in the management of type 2 diabetes mellitus (T2DM) due to their reported pronounced biological effects in relation to multiple metabolic factors associated with diabetes. Hence, in this regard, we have comprehensively reviewed the potential biological effects of isoflavonoids, particularly biochanin A, genistein, daidzein, glycitein, and formononetin on metabolic disorders and long-term complications induced by T2DM in order to understand whether they can be future candidates as a safe antidiabetic agent. Based on in-depth in vitro and in vivo studies evaluations, isoflavonoids have been found to activate gene expression through the stimulation of peroxisome proliferator-activated receptors (PPARs) (α, γ), modulate carbohydrate metabolism, regulate hyperglycemia, induce dyslipidemia, lessen insulin resistance, and modify adipocyte differentiation and tissue metabolism. Moreover, these natural compounds have also been found to attenuate oxidative stress through the oxidative signaling process and inflammatory mechanism. Hence, isoflavonoids have been envisioned to be able to prevent and slow down the progression of long-term diabetes complications including cardiovascular disease, nephropathy, neuropathy, and retinopathy. Further thoroughgoing investigations in human clinical studies are strongly recommended to obtain the optimum and specific dose and regimen required for supplementation with isoflavonoids and derivatives in diabetic patients.